NCT06051357View on ClinicalTrials.gov

Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

March 25, 2024

Study Completion Date

March 25, 2024

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG

HRS-5965 tablets

HRS-5965 tablets for 12 weeks

Trial Locations (2)

100730

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

300020

The Blood Disease Hospital of the Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors

lead

Chengdu Suncadia Medicine Co., Ltd.

INDUSTRY

NCT06051357 - Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria | Biotech Hunter | Biotech Hunter